FINWIRES · TerminalLIVE
FINWIRES

Rate Increases Have Limited Impact on Japanese Borrowers' Credit Quality, S&P Says

By

-- Increasing interest rates will not have a significant effect on Japanese borrowers' creditworthiness, although repayment burdens could intensify if the rise in rates continues, S&P Global Ratings said in a Tuesday release.

The rating agency expects limited impact on repayment capacity from higher interest rates as residential mortgage-backed securities (RMBS) are usually backed by fixed-rate housing loans, S&P said.

However, rate increases could heighten total borrowing, especially under increased real estate prices, S&P said.

The spike in housing prices is likely due to increased employment costs and a sustained rise in imported material prices, the rating agency said.

Still, S&P expects that even under the most severe stress scenario, tranches to be downgraded would only have a 17% share of all rated RMBS transactions and still lead to ratings of A+ or higher.

Related Articles

International

U.S. Energy Production Climbs 3% YoY in January, EIA Reports

U.S. primary energy production rose 3% year over year in January to 9.1 quadrillion British thermal units, the U.S. Energy Information Administration said in its Monthly Energy Review released Monday.Total fossil fuels production in January was made up of 46% dry natural gas, 31% crude oil, 12% crude oil and 11% natural gas plant liquids, the EIA reported.Total renewable energy production was composed of 56% biomass, 20% wind, 12% hydroelectric power, 11% solar and 1% geothermal energy, according to the agency.U.S. natural gas plant liquids production was 7% higher in January than in the year-ago month. Dry natural gas production and renewable energy production each climbed 4%. Nuclear electric power production and coal production each increased 2%. Crude oil production rose 1%.

$CLX1$LCOX1$NGV1$UNG$UNL$USO
Asia

CanSino Biologics Widens Loss in Q1

CanSino Biologics (HKG:6185, SHA:688185) widened its attributable loss in the first quarter of 2026 to 40.4 million yuan from 11.5 million yuan a year prior, according to a Tuesday Hong Kong bourse filing.Loss per share was 0.16 yuan, compared with 0.05 yuan in the corresponding period of the previous fiscal year.Operating revenue jumped 39% to 190.3 million yuan from 137.2 million yuan in the year-ago period, amid the company's expanding commercial product portfolio, increasing overseas presence, and robust sales of hte MCV4 vaccine.The vaccine manufacturer attributed the wider loss to a higher operating cost; a rise in selling, administrative, and R&D expenses; and a lower other income related to government grants and international funding support.

$HKG:6185$SHA:688185
Japan

WTI Crude Oil Futures Jump 3.5% to $99.72 Pre-Bell; Brent Futures Rise 2.9% to $111.39